Muhammad Shahzou Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammad Shahzou Shah has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Abia Khalid Mir
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication Hassaan Abid
1 shared publication- Javeria Nawaz
Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Maheen Sheraz
Department of Medicine, Continental Medical College, Lahore, Pakistan
1 shared publication - Minhal Faisal
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Muhammad Abdullah Ali
Khyber Medical College Peshawar Pakistan
1 shared publication
Latest Publications
- 15 June 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (7) , 172
Olanzapine for chemotherapy-induced nausea and vomiting in breast cancer: a systematic review and meta-analysis of prospective randomised controlled trials
Purpose Chemotherapy-induced nausea and vomiting (CINV) remains a significant problem for breast cancer patients receiving highly emetogenic chemotherapy despite routine antiemetic practice. In this systematic review and meta-analysis we aim to examine the efficacy and safety of olanzapine with regular antiemetic treatment for CINV prevention in breast cancer patients. Methods Following PRISMA 2020 standards, we searched PubMed, Cochrane Library, Google scholar, and ClinicalTrials.gov. We retrieved RCTs exclusively, comparing olanzapine with placebo or routine care in breast cancer patients undergoing anthracycline-based chemotherapy. The protocol was registered to PROSPERO (CRD420251087309). The primary outcomes assessed were complete response (defined as no emesis and no rescue medication use) and total control (defined as no nausea, no emesis, and no rescue medication use). Certainty of evidence was assessed using the GRADE approach. Results Four RCTs involving 857 patients were included. Compared with placebo or standard antiemetic therapy alone, olanzapine significantly improved complete response rates (4 studies, 857 patients; RR 1.58, 95% CI 1.35–1.85; I² = 0%) and total control (2 studies, 600 patients; RR 1.93, 95% CI 1.49–2.50; I² = 0%). Subgroup analysis showed no statistically significant difference between 5 mg and 10 mg doses. Olanzapine decreased acute nausea (3 studies, 377 patients; RR 1.32, 95% CI 1.03–1.69, I² = 63.4%) and delayed nausea (3 studies, 377 patients; RR 1.22, 95% CI 1.06–1.41, I² = 0%). The overall impact on nausea control was not statistically significant and showed considerable heterogeneity (3 studies, 377 patients; RR 1.42, 95% CI 0.48–4.15; I² = 88.0%). Subgroup analysis showed no statistically significant difference between 5 mg and 10 mg doses. Side effects, including sedation, fatigue, sleeplessness, extrapyramidal symptoms, and increased appetite were significantly attributable to olanzapine. GRADE assessment showed low certainty evidence for complete response, total control, and delayed nausea outcomes, while evidence for acute complete response, acute nausea control, and overall nausea control was rated very low certainty due to risk of bias, inconsistency, and imprecision. Conclusion Olanzapine significantly enhances CINV prevention in breast cancer patients, with positive outcomes for both 5 mg and 10 mg doses. Although increased sedation occurred, it was generally well-tolerated.
- 15 June 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (7) , 172
Olanzapine for chemotherapy-induced nausea and vomiting in breast cancer: a systematic review and meta-analysis of prospective randomised controlled trials
Purpose Chemotherapy-induced nausea and vomiting (CINV) remains a significant problem for breast cancer patients receiving highly emetogenic chemotherapy despite routine antiemetic practice. In this systematic review and meta-analysis we aim to examine the efficacy and safety of olanzapine with regular antiemetic treatment for CINV prevention in breast cancer patients. Methods Following PRISMA 2020 standards, we searched PubMed, Cochrane Library, Google scholar, and ClinicalTrials.gov. We retrieved RCTs exclusively, comparing olanzapine with placebo or routine care in breast cancer patients undergoing anthracycline-based chemotherapy. The protocol was registered to PROSPERO (CRD420251087309). The primary outcomes assessed were complete response (defined as no emesis and no rescue medication use) and total control (defined as no nausea, no emesis, and no rescue medication use). Certainty of evidence was assessed using the GRADE approach. Results Four RCTs involving 857 patients were included. Compared with placebo or standard antiemetic therapy alone, olanzapine significantly improved complete response rates (4 studies, 857 patients; RR 1.58, 95% CI 1.35–1.85; I² = 0%) and total control (2 studies, 600 patients; RR 1.93, 95% CI 1.49–2.50; I² = 0%). Subgroup analysis showed no statistically significant difference between 5 mg and 10 mg doses. Olanzapine decreased acute nausea (3 studies, 377 patients; RR 1.32, 95% CI 1.03–1.69, I² = 63.4%) and delayed nausea (3 studies, 377 patients; RR 1.22, 95% CI 1.06–1.41, I² = 0%). The overall impact on nausea control was not statistically significant and showed considerable heterogeneity (3 studies, 377 patients; RR 1.42, 95% CI 0.48–4.15; I² = 88.0%). Subgroup analysis showed no statistically significant difference between 5 mg and 10 mg doses. Side effects, including sedation, fatigue, sleeplessness, extrapyramidal symptoms, and increased appetite were significantly attributable to olanzapine. GRADE assessment showed low certainty evidence for complete response, total control, and delayed nausea outcomes, while evidence for acute complete response, acute nausea control, and overall nausea control was rated very low certainty due to risk of bias, inconsistency, and imprecision. Conclusion Olanzapine significantly enhances CINV prevention in breast cancer patients, with positive outcomes for both 5 mg and 10 mg doses. Although increased sedation occurred, it was generally well-tolerated.
- Open Access
- 27 March 2026
- Published by S. Karger AG in Endocrinology Insights
- p. 1-10
Cardiovascular Disease Mortality in Patients with Hypothyroidism: A 22-Year National Analysis of US Trends and Disparities
Introduction: Hypothyroidism is a prevalent endocrine disorder that has been linked to adverse cardiovascular outcomes. However, national-level trends and disparities in cardiovascular disease (CVD)-related mortality among individuals with hypothyroidism remain incompletely characterized. This study aimed to evaluate long-term temporal trends and demographic disparities in CVD mortality among US adults with hypothyroidism. Methods: We conducted a retrospective population-based analysis using death certificate data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database from 1999 to 2020. Adults aged ≥25 years with hypothyroidism were identified using ICD-10 codes E02–E03, with CVD-related deaths defined by ICD-10 codes I00–I99. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 US standard population. Temporal trends were analyzed using joinpoint regression to estimate annual percent change (APC), and subgroup analyses were performed by sex, race/ethnicity, age group, urban-rural status, and place of death. Results: Between 1999 and 2020, 382,906 CVD-related deaths were associated with hypothyroidism, corresponding to an overall AAMR of 8.00 per 100,000. Mortality rates increased steadily over the study period, peaking at 10.12 per 100,000 in 2020, with the most pronounced rise occurring between 2018 and 2020 (APC 14.01%). Women accounted for nearly three times as many deaths as men, although mortality rates increased more rapidly among men. Non-Hispanic white individuals exhibited the highest absolute mortality burden, while Hispanic populations experienced the fastest growth in mortality rates. The largest relative increases were observed among adults aged 35–44 and 45–54 years. Mortality rates were consistently higher in rural compared with urban areas, and the majority of deaths occurred in long-term care facilities. Conclusion: CVD-related mortality among US adults with hypothyroidism has risen substantially over the past two decades, with marked disparities across sex, age, race/ethnicity, and geographic location. These findings highlight the need for targeted cardiovascular risk assessment, early detection of hypothyroidism, and integrated management strategies, particularly in high-risk and underserved populations, to mitigate rising mortality and reduce health inequities.
- 27 March 2026
- Published by S. Karger AG in Endocrinology Insights
- p. 1-10
Open AccessCardiovascular Disease Mortality in Patients with Hypothyroidism: A 22-Year National Analysis of US Trends and Disparities
Introduction: Hypothyroidism is a prevalent endocrine disorder that has been linked to adverse cardiovascular outcomes. However, national-level trends and disparities in cardiovascular disease (CVD)-related mortality among individuals with hypothyroidism remain incompletely characterized. This study aimed to evaluate long-term temporal trends and demographic disparities in CVD mortality among US adults with hypothyroidism. Methods: We conducted a retrospective population-based analysis using death certificate data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database from 1999 to 2020. Adults aged ≥25 years with hypothyroidism were identified using ICD-10 codes E02–E03, with CVD-related deaths defined by ICD-10 codes I00–I99. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 US standard population. Temporal trends were analyzed using joinpoint regression to estimate annual percent change (APC), and subgroup analyses were performed by sex, race/ethnicity, age group, urban-rural status, and place of death. Results: Between 1999 and 2020, 382,906 CVD-related deaths were associated with hypothyroidism, corresponding to an overall AAMR of 8.00 per 100,000. Mortality rates increased steadily over the study period, peaking at 10.12 per 100,000 in 2020, with the most pronounced rise occurring between 2018 and 2020 (APC 14.01%). Women accounted for nearly three times as many deaths as men, although mortality rates increased more rapidly among men. Non-Hispanic white individuals exhibited the highest absolute mortality burden, while Hispanic populations experienced the fastest growth in mortality rates. The largest relative increases were observed among adults aged 35–44 and 45–54 years. Mortality rates were consistently higher in rural compared with urban areas, and the majority of deaths occurred in long-term care facilities. Conclusion: CVD-related mortality among US adults with hypothyroidism has risen substantially over the past two decades, with marked disparities across sex, age, race/ethnicity, and geographic location. These findings highlight the need for targeted cardiovascular risk assessment, early detection of hypothyroidism, and integrated management strategies, particularly in high-risk and underserved populations, to mitigate rising mortality and reduce health inequities.